Investigation Of FDA Employee Misconduct Charges Returns to OIG
This article was originally published in The Tan Sheet
Executive SummaryA "stronger appearance of impartiality, integrity" will result from returning investigative authority over allegations of FDA employee misconduct to the Department of Health and Human Services Office of Inspector General, a House Energy and Commerce Committee aide says
You may also be interested in...
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.